Skip to main content
. 2020 Jan 27;11(1):69. doi: 10.1038/s41419-020-2266-x

Table 1.

Renal cell carcinoma cell lines, inclusive their SETD2 and VHL status, used in this study.

Research resource identifier Cell line collections Disease VHL status; SETD2 status (COSMIC)
+ for wild-type gene
− for mutated gene
References
ACHN RRID:CVCL_1067 ATCC® CRL-1611™; ECACC 88100508

Renal cell carcinoma, derived from metastatic site,

male, 22Y

VHL+; SETD2+ 33,55,56
Caki-1 RRID:CVCL_0234 ATCC® HTB-46™; DSMZ ACC-731

Renal cell carcinoma, derived from metastatic site,

male, 49Y

VHL+; SETD2 33,56,57
Caki-2 RRID:CVCL_0235 ATCC® HTB-47™; DSMZ ACC-54; ECACC 93120819

Renal cell carcinoma, derived from primary tumor site,

male, 69Y

VHL−; SETD2+ 33,57
A498 RRID:CVCL_1056 ATCC® HTB-44™; DSMZ ACC-55

Renal cell carcinoma, derived from primary tumor site,

male, 52Y

VHL; SETD2 33,56,57
RCC-FG2 RRID:CVCL_5873 CLS #300249

Renal cell carcinoma, derived from primary tumor site,

male, 77Y

VHL−; SETD2 58,59
769-P RRID:CVCL_1050 ATCC® CRL-1933™; CLS #300106

Renal cell carcinoma, derived from primary tumor site,

female, 63Y

VHL−; SETD2+ 60,61

ATCC American Type Culture Collection, DZME German Collection of Microorganisms and Cell Culture; ECACC European Collection of Authenticated Cell Cultures, CLS Cell Line Service, COSMIC Catalog of Somatic Mutations in Cancer